Cardiac Science Corp (MM) (NASDAQ:CSCX)
Historical Stock Chart
5 Years : From Jan 2012 to Jan 2017
Levi & Korsinsky is investigating the Board of Directors of Cardiac
Science Corporation (“Cardiac Science” or the “Company”) (NasdaqGM:CSCX)
for possible breaches of fiduciary duty and other violations of state
law in connection with their attempt to sell the Company to Opto
Circuits Limited (“Opto Circuits”). Under the terms of the transaction,
Cardiac Science shareholders will receive $2.30 in cash for each share
of Cardiac Science common stock. The boards of directors of both
companies have unanimously approved the transaction, which will take the
form of an all-cash tender offer by a wholly-owned subsidiary of Opto
Circuits, followed by a second-step merger.
Click here to learn how to join the action: http://www.zlk.com/cardiac-science-cscx.html,
or call: 877-363-5972.
The investigation concerns whether the Cardiac Science Board of
Directors breached their fiduciary duties to Cardiac Science
stockholders by failing to adequately shop the Company before entering
into this transaction and whether Opto Circuits is underpaying for
Cardiac Science shares, thus unlawfully harming Cardiac Science
stockholders. In particular, at least one analyst set a price target for
Cardiac Science stock at $6.00 per share and Cardiac Science stock has
traded as high as $2.48 per share as recently as August 4, 2010.
If you own common stock in Cardiac Science and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email at [email protected]
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/cardiac-science-cscx.html.
Levi & Korsinsky has expertise in prosecuting investor securities
litigation and extensive experience in actions involving financial fraud
and represents investors throughout the nation, concentrating its
practice in securities and shareholder litigation. The attorneys at Levi
& Korsinsky have been appointed by numerous courts throughout the
country to serve as lead counsel on behalf of shareholders in major
litigations involving mergers and acquisitions. For more information,
please feel free to contact any of the attorneys listed below.